Remsima

DRUG2 trials

Sponsors

Ghurki Trust and Teaching Hospital, Mundipharma

Conditions

PsoriasisReumatoid Arthritis/Rheumatism

Phase 4

An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima* (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn*s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.

Active, not recruitingNL-OMON43846

MundipharmaReumatoid Arthritis/Rheumatism

Start: 2015-06-05Target: 129Updated: 2024-02-28

Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis

CompletedNCT06043752

Ghurki Trust and Teaching HospitalPsoriasis

Start: 2022-03-10End: 2023-08-05Updated: 2023-09-21